Goldman Sachs European Express focuses on UK homebuilders, consumer ingredients, Smith & Nephew, Stellantis, and macro markets

Overview

This is a Goldman Sachs European Express report that summarizes research across multiple industries and companies, macro strategy, global themes, and corporate activity information. Core coverage includes UK homebuilders, European consumer ingredients, Smith & Nephew, Stellantis, European and US macro markets, Chinese humanoid robots, and follow-up meeting arrangements. The overall conclusion is not a single-direction buy or sell call, but rather an emphasis on selective positioning amid macro pressure, cost inflation, and valuation divergence.

Core views

In UK homebuilding, the market's punishment of the sector may already be excessive, but slowing sales rates and regional exposure differences mean investors should prioritize companies with stronger margin resilience and lower exposure to southern UK and London markets. In consumer ingredients, the demand and cost inflation environment remains more supportive than investors expect, but raw material, customer structure, and regional revenue risks need to be assessed. Smith & Nephew's near-term FY26 growth expectations were lowered, but product launches, momentum in sports medicine, and easing China headwinds support improving growth after FY27. Stellantis' 2030 growth targets are above market expectations, but delivery depends on cost savings and cash generation. On the macro side, rising European rates are pressuring equity valuations, but structural themes such as AI, defense, electrification, and infrastructure capital spending are still recommended areas of focus.

Analysis framework

The report uses a multi-theme express format, combining company ratings, industry frameworks, valuation multiples, earnings forecast revisions, strategic plan targets, and macro fund flow/rate sensitivity. For individual companies, it focuses on comparing valuations, earnings forecasts, and operating drivers; for industries, it emphasizes building risk exposure dimensions; and for macro, it focuses on rates, fiscal pressure, fund positioning rotation, and structural themes.

Methodology notes

• Industry resilience assessmentFour-dimensional stagflation resilience framework for consumer ingredients

  Assess companies' relative resilience under stagflation risk across four dimensions: discretionary demand exposure, dependence on synthetic raw materials, concentration of local and regional customers, and share of revenue from emerging markets.

  This framework is used to compare the resilience of consumer ingredient companies such as Kerry, Novonesis, DSM-Firmenich, Givaudan, Symrise, and Croda under slowing demand, rising petrochemical feedstock prices, and regional revenue volatility.

• Valuation and earnings forecastsValuation combining multiples and DCF

  The Smith & Nephew target price revision uses a 50/50 multiples and DCF approach, and lowers the P/E multiple from 18x to 16x.

  Analysts lowered FY26-FY28 revenue and EBIT estimates by 1%-2%, but adjusted EPS by 0%-1% due to a higher buyback assumption, with the target price reduced 8% because of estimate changes and multiple compression.

• Macro strategyEquity interest-rate sensitivity analysis

  Assess the pressure on European equities in a higher-yield environment through historical stock-bond correlation and rate thresholds.

  The report warns that traditional historical frameworks should be used cautiously, because stronger growth-stock balance sheets, style convergence, and industry reclassification have weakened past definitions, though higher yields may still increase valuation pressure.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• UK Homebuilders

  Industry theme and multi-name rating updates

  Strengths

  After an approximately 30% de-rating, sector valuations are near 15-year lows, and some companies have margin resilience, pricing resilience, outlet expansion, and cost synergy potential.

  Weaknesses

  Sales rates are expected to soften, southern UK and London markets are under pressure, and some companies' valuation premiums are hard to justify.

  Comparison

  Persimmon, Barratt Redrow, and Vistry are viewed as relatively more attractive; Taylor Wimpey was downgraded to Sell; Berkeley remains Sell due to London exposure.

  Risks

  Mortgage rates, slowing demand, regional pricing pressure, and changes in fiscal policy and consumer confidence.

• Consumer Ingredients

  Industry resilience framework

  Strengths

  Novonesis has lower discretionary demand exposure and lower dependence on synthetic inputs; Croda's pricing power and upside from biosurfactant capacity are seen as underappreciated.

  Weaknesses

  Kerry has higher discretionary demand exposure, while DSM-Firmenich and Givaudan are more dependent on synthetic raw materials and may be pressured by rising petrochemical prices.

  Comparison

  Novonesis is viewed as the top pick and is on the Buy-rated Conviction List; Givaudan has the highest share of emerging-market revenue, while Croda has higher dependence on APAC.

  Risks

  Stagflation, rising petrochemical feedstock prices, regional customer concentration, and volatility in emerging-market demand.

• Smith & Nephew PLC (SN.L / SNN.US)

  Company research and rating view

  Strengths

  Key product launches, momentum in sports medicine, and easing China headwinds are expected to drive organic growth acceleration to 6%-7% after FY27E.

  Weaknesses

  1Q26 momentum was soft, the FY26 organic growth forecast was cut from +6% to +5%, and FY26-FY28 revenue and EBIT estimates were lowered by 1%-2%.

  Comparison

  Analysts maintain Buy, believing consensus and the current valuation do not fully reflect the post-FY27 growth improvement; the target price was cut 8% as the valuation multiple was reduced from 18x to 16x.

  Risks

  Product launch contributions coming in below expectations, slower-than-expected China recovery, slowing sports medicine growth, and further valuation multiple compression.

• Stellantis NV (STLAM.MI)

  Company strategy and Investor Day update

  Strengths

  FaSTLAne 2030 sets out a €60bn investment plan, development cycles shortened to about 24 months, €6bn annualized cost cuts by 2028, and 2028/2030 AOI targets of 5%/7%.

  Weaknesses

  AOI improvement is highly dependent on execution of cost savings, and cash generation is critical; the industrial free cash flow target is difficult to achieve.

  Comparison

  The 2028/2030 AOI targets are above consensus of 4.4%/4.7% and above parts of Goldman Sachs' expectations of 5.0%/6.2%, but there is still disagreement over free cash flow assumptions; the rating is Neutral.

  Risks

  Failure to execute cost savings, weaker-than-expected returns on brand investment, auto demand and pricing pressure, and capex dragging on cash flow.

• European equities and macro markets

  Macro strategy backdrop

  Strengths

  European corporate balance sheets are broadly solid, with structural themes including AI, defense spending, power and electrification, and infrastructure/capital expenditure cycles.

  Weaknesses

  Higher yields are pressuring equity valuations, while UK energy prices, interest rates, and growth pressures are creating fiscal constraints.

  Comparison

  US fund positioning shows both mutual funds and hedge funds rotating from software into semiconductors, with hedge funds' semiconductor long weighting at a record high.

  Risks

  Rising rates, fiscal tightening, geopolitics, reversal of style rotation, and crowded structural-theme trades.

• China Humanoid Robot

  Global thematic research summary

  Strengths

  The combination of VLA/VTLA models with world models improves planning and robustness, and commercialization in industrial and logistics scenarios is expanding.

  Weaknesses

  High-quality real-world data remains the main bottleneck to scaling, and most deployments are still at the proof-of-concept stage.

  Comparison

  The report expects large-scale deployment to gradually advance during 2027-2029 as data accumulates and costs decline.

  Risks

  Insufficient data acquisition, slower-than-expected cost declines, insufficient validation of commercialization scenarios, and model reliability constraints.

Key data

• Magnitude of de-rating for UK homebuildersApproximately 30%The market implies about 5% terminal ROE, below analysts' estimates of 6.4% for FY26E and 7.1% for FY28E.
• Expected volume growth for UK homebuilders2026 +3%, 2027 +4%Sales rates are expected to weaken, but outlet expansion supports total volume growth, while margin pressure is expected to be moderate.
• Taylor Wimpey valuation2026E P/E 13.8x vs peers 9.5xThe premium valuation does not match the operating pressure in its southern UK and London businesses, so it was downgraded to Sell.
• Smith & Nephew FY26 organic growth forecast+5%, previously +6%The reduction reflects softer 1Q26 momentum and a more conservative timing assumption for product launch contributions.
• Smith & Nephew organic growth potential after FY27E6%-7%Supported by key product launches, momentum in sports medicine, and easing China headwinds; analysts believe consensus and the current valuation do not yet fully reflect this.
• Smith & Nephew upside36%Buy is maintained, but the target price was cut 8% due to earnings estimate changes and valuation multiple adjustments.
• Stellantis investment plan€60bnFaSTLAne 2030 is a five-year strategic plan, with about 70% of the €36bn brand and product investment concentrated in core global brands such as Jeep, Ram, Peugeot, and FIAT.
• Stellantis annualized cost reduction target€6bn by 2028From the Value Creation Program, supporting targets to raise 2028/2030 AOI to 5%/7%.
• Impact of UK fiscal pressureApproximately £10bnHigher energy prices, higher interest rates, and lower growth could raise OBR borrowing forecasts and reduce buffer space under fiscal rules.

Impact & implications

For portfolios, the report supports structural stock selection under European cyclical and macro pressure rather than simply buying low-valuation sectors. In UK homebuilding, investors can focus on margins, regional exposure, and outlet expansion capability; in consumer ingredients, preference should be given to companies with stronger raw material and demand resilience; in medical devices, Smith & Nephew's near-term forecast cut may create volatility, but if the FY27 growth acceleration materializes, there is room for valuation recovery; in autos, Stellantis' strategic targets provide a medium- to long-term upside narrative, but cash flow and cost-cut execution are the key constraints.

Risks

• Rising European rates and changes in stock-bond correlation may continue to pressure equity valuations.
• UK housing demand, mortgage costs, and regional pricing pressure may lead to volumes and margins below expectations.
• Consumer ingredient companies face risks from stagflation, rising petrochemical feedstock prices, and regional revenue volatility.
• Smith & Nephew's FY27 growth acceleration depends on product launches, sports medicine momentum, and improving demand in China.
• Stellantis' 2030 targets are highly dependent on execution of cost cuts, returns on brand investment, and cash flow generation.
• UK fiscal pressure may trigger tax or policy adjustments, affecting consumer and business confidence.

What to watch

• Sales rates, outlet expansion, and price changes in southern UK/London markets for UK homebuilders.
• Whether Taylor Wimpey's FY26 operating performance and valuation premium continue to compress.
• The actual performance of Novonesis, Croda, Kerry, DSM-Firmenich, and Givaudan in response to changes in raw material costs and demand.
• Smith & Nephew's quarterly FY26 organic growth, product launch contribution, momentum in the sports medicine business, and recovery of its China business.
• The cost-reduction progress, AOI margin, and industrial free cash flow of Stellantis' Value Creation Program.
• The path of European yields, UK fiscal events, and the persistence of fund rotation from software to semiconductors.
• The accumulation of real-world data for Chinese humanoid robots, cost declines, and progress toward scaled deployment in 2027-2029.